<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>51</volume><submitter>Procopio A</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Transcatheter left atrial appendage occlusion (LAAO) has emerged as an alternative treatment for stroke prevention in patients with atrial fibrillation (AF) at high risk of thromboembolism, who cannot tolerate long-term oral anticoagulation (OAC). Questions persist regarding effectiveness and safety of this treatment and the optimal post-interventional antithrombotic regimen after LAAO.&lt;h4>Methods&lt;/h4>We retrospectively gathered data from 428 patients who underwent percutaneous LAAO in 6 Italian high-volume centres, aimed at describing the real-world utilization, safety, and effectiveness of LAAO procedures, also assessing the clinical outcomes associated with different antithrombotic strategies.&lt;h4>Results&lt;/h4>Among the entire population, 20 (4.7 %) patients experienced a combination of pericardial effusion and periprocedural major bleeding: 8 (1.9 %) pericardial effusion, 1 (0.3 %) fatal bleeding, and 3 (0.7 %) non-fatal procedural major bleeding. Patients were discharged with different antithrombotic regimens: dual (DAPT) (27 %) or single (SAPT) (26 %) antiplatelet therapy, OAC (27 %), other antithrombotic regimens (14 %). Very few patients were not prescribed with antithrombotic drugs (6 %). At a medium 523 ± 58 days follow-up, 14 patients (3.3 %) experienced all-cause death, 6 patients (1.4 %) cardiovascular death, 3 patients (0.7 %) major bleeding, 10 patients (2.6 %) clinically relevant non-major bleeding, and 3 patients (0.7 %) ischemic stroke. At survival analysis, with DAPT as the reference group, OAC therapy was associated with better outcomes.&lt;h4>Conclusions&lt;/h4>Our findings confirm that LAAO is a safe procedure. Different individualized post-discharge antithrombotic regimens are now adopted, likely driven by the perceived thrombotic and hemorrhagic risk. The incidence of both ischemic and bleeding events tends to be low.</pubmed_abstract><journal>International journal of cardiology. Heart &amp; vasculature</journal><pagination>101391</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10979264</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience.</pubmed_title><pmcid>PMC10979264</pmcid><pubmed_authors>Gragnano F</pubmed_authors><pubmed_authors>Calabro P</pubmed_authors><pubmed_authors>Gallina S</pubmed_authors><pubmed_authors>Procopio A</pubmed_authors><pubmed_authors>Sacchetta D</pubmed_authors><pubmed_authors>Russo AD</pubmed_authors><pubmed_authors>Renda G</pubmed_authors><pubmed_authors>Patti G</pubmed_authors><pubmed_authors>Radico F</pubmed_authors><pubmed_authors>Ghiglieno C</pubmed_authors><pubmed_authors>Barbarossa A</pubmed_authors><pubmed_authors>Ricci F</pubmed_authors><pubmed_authors>Filtz A</pubmed_authors><pubmed_authors>Faustino M</pubmed_authors><pubmed_authors>Fassini G</pubmed_authors></additional><is_claimable>false</is_claimable><name>A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience.</name><description>&lt;h4>Background&lt;/h4>Transcatheter left atrial appendage occlusion (LAAO) has emerged as an alternative treatment for stroke prevention in patients with atrial fibrillation (AF) at high risk of thromboembolism, who cannot tolerate long-term oral anticoagulation (OAC). Questions persist regarding effectiveness and safety of this treatment and the optimal post-interventional antithrombotic regimen after LAAO.&lt;h4>Methods&lt;/h4>We retrospectively gathered data from 428 patients who underwent percutaneous LAAO in 6 Italian high-volume centres, aimed at describing the real-world utilization, safety, and effectiveness of LAAO procedures, also assessing the clinical outcomes associated with different antithrombotic strategies.&lt;h4>Results&lt;/h4>Among the entire population, 20 (4.7 %) patients experienced a combination of pericardial effusion and periprocedural major bleeding: 8 (1.9 %) pericardial effusion, 1 (0.3 %) fatal bleeding, and 3 (0.7 %) non-fatal procedural major bleeding. Patients were discharged with different antithrombotic regimens: dual (DAPT) (27 %) or single (SAPT) (26 %) antiplatelet therapy, OAC (27 %), other antithrombotic regimens (14 %). Very few patients were not prescribed with antithrombotic drugs (6 %). At a medium 523 ± 58 days follow-up, 14 patients (3.3 %) experienced all-cause death, 6 patients (1.4 %) cardiovascular death, 3 patients (0.7 %) major bleeding, 10 patients (2.6 %) clinically relevant non-major bleeding, and 3 patients (0.7 %) ischemic stroke. At survival analysis, with DAPT as the reference group, OAC therapy was associated with better outcomes.&lt;h4>Conclusions&lt;/h4>Our findings confirm that LAAO is a safe procedure. Different individualized post-discharge antithrombotic regimens are now adopted, likely driven by the perceived thrombotic and hemorrhagic risk. The incidence of both ischemic and bleeding events tends to be low.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2025-04-25T18:59:40.588Z</modification><creation>2025-04-06T07:45:56.732Z</creation></dates><accession>S-EPMC10979264</accession><cross_references><pubmed>38560514</pubmed><doi>10.1016/j.ijcha.2024.101391</doi></cross_references></HashMap>